AbbVie turns to tau for Alzheimer’s in $1.1bn deal

pharmafile | February 21, 2018 | News story | Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical 

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion with Voyager Therapeutics.

The news is a positive note amongst a fair amount of doom-and-gloom in the hopes of finding a treatment for Alzheimer’s in the near future, perhaps exemplified best by Pfizer’s decision to exit the neuroscience area at the beginning of the year.

However, AbbVie remains undaunted and has decided to pursue the tau pathway in the hope that it could provide better potential for a treatment, where amyloid-targeting therapies have struggled of late.

Voyager specialises in gene therapy, with expertise in creating vectorised antibodies directed against tau protein in the brain. This form of delivery means that a potential treatment could bypass the blood-brain barrier, delivering a one-time treatment.

Current therapies being explored are limited to weekly or biweekly infusions, where only a small amount of drug is able to access the brain.

Tau is a naturally occurring protein in the brain, known to promote cellular stability and function. However, it has been observed that, in an unhealthy brain, tau is seen to accumulate into ‘tau tangles’, which has been correlated to neurodegeneration.

“AbbVie is focused on developing treatments to meet the crushing public health crisis presented by Alzheimer’s and other neurodegenerative diseases,” said Jim Sullivan, Vice President, Pharmaceutical Discovery, AbbVie. “Voyager’s vectorised antibody platform presents an innovative approach to addressing challenges in treating neurological disorders associated with the administration of biologic therapies. This collaboration has the potential to address the needs of patients who live with conditions such as Alzheimer’s disease, progressive supranuclear palsy and frontotemporal dementia.”

Voyager will receive $69 million as an upfront payment, whilst potentially being in-line to receive $155 million on successful preclinical and Phase 1 readouts. There is a further heavy payload of $895 million to be mined should Voyager reach developmental and regulatory milestones.

Though it may seem like a generous sum, any approved Alzheimer’s treatment would reap serious rewards for the company licensed to sell the product. 10% of the population, over the age 65, has Alzheimer’s dementia in the US and the market is therefore substantial.

Ben Hargreaves

Related Content

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics …

AbbVie to acquire ImmunoGen for approximately $10.1bn

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy …

Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap

Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement …

Latest content